**Supplemental tables**

**Supplemental Table 1. Occurrence of TTC by comorbidities of the patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Comorbidity** | **No TTC**  **N=97** | **TTC**  **N=39** | **Yates χ2** |
| Hypertension (Yes/No) | 54/43 | 19/20 | 0.297 n.s. |
| Arrhytmias or conduction disturbances (Yes/No) | 3/94 | 1/38 | 0.000 n.s. |
| Hypercholesterinemia/trigliceridaemia (Yes/No) | 11/86 | 4/35 | 0.000 n.s. |
| Diabetes mellitus (Yes/No) | 4/93 | 1/38 | 0.000 n.s. |
| Hypothyreosis (Yes/No) | 3/94 | 0/39 | 0.000 n.s. |
| Hyperthyreosis (Yes/No) | 0/97 | 1/38 | 0.224 n.s. |
| Smoking (Yes/No) | 47/50 | 19/20 | 0.000 n.s. |
| Obesity (Yes/No) | 26/71 | 7/32 | 0.754 n.s. |

**Supplemental Table 2. Severity of TTC by comorbidities of the patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Comorbidity** | **No TTC**  **N=97** | **Moderate TTC**  **N=28** | **Severe TTC**  **N=11** | **χ2** |
| Hypertension (Yes/No) | 54/43 | 14/14 | 5/6 | 0.606 n.s. |
| Arrhytmia or conduction disturbance (Yes/No) | 3/94 | 1/27 | 0/11 | 0.380 n.s. |
| Hypercholesterin/  Hypertrigliceridaemia (Yes/No) | 11/86 | 2/26 | 2/9 | 1.014 n.s. |
| Diabetes mellitus (Yes/No) | 4/93 | 0/28 | 1/10 | 2.034 n.s. |
| Hypothyreosis (Yes/No) | 3/94 | 0/28 | 0/11 | 1.233 n.s. |
| Hyperthyreosis (Yes/No) | 0/97 | 1/27 | 0/11 | 3.886 n.s. |
| Smoking (Yes/No) | 47/50 | 13/15 | 6/5 | 0.209 n.s. |
| Obesity (Yes/No) | 26/71 | 6/22 | 1/10 | 1.841 n.s. |

**Supplemental Table 3**. Results of general linear models testing the differences in normetenephrin concentration between study groups and the effect of arterenol and dobutrex on normetanephrin concentration on days 1 and 30.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Day** | **Effect** | **Coefficient ± S.E.** | **F (df1, df2)** | **p** |
| Day 1 | Study group, control vs. moderate TTC | -216.0 ± 256.32 | 85.475 (2, 118) | p < 0.0001 |
| Study group, control vs. severe TTC | -95.5 ± 289.59 |
| Arterenol | 243.7 ± 16.56 | 256.888 (1,118) | p < 0.0001 |
| Dobutamin | 3.4 ± 1.44 | 5.545 (1,118) | p < 0.0001 |
| Day 30 | Study group, control vs. moderate TTC | -747.6 ± 352.80 | 2.576 (1,68) | p = 0.084 |
| Study group, control vs. severe TTC | -444.1 ± 374.6 |
| Arterenol | 111.8 ± 113.8 | 0.965 | 0.329 |